Products
AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
Freemium model, plan pricing not identified yet
Creators
Tom Rudovsky
No social account linked
Launched
8mo ago
2026-03-27 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    solve jigsaw puzzles, color them, print and view them in 3D

    Mar 27 · 8mo agoLaunch page

Store data

Google Play
Google Play Google Play
Update date not synced
Rating
Rating not syncedRating count not synced
New ratings last mo
—
Price & IAP
FreeIAP data not synced
Current version
—Store metadata

Store assets, rating histograms, install tiers, and screenshots are synced from Apple App Store, Google Play, and Chrome Web Store.

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct36%
  • Organic Search33%
  • Referrals12%
  • Social6%
  • Other14%

Countries

  • India100%

Search

Domain authority —Domain registered 2026-03-22

KeywordMonthly volume
how to solve the corn cob puzzle300

Traffic data: Vaneform

Pricing

Website does not list public plan prices.

Trial: None · Observed 2026-11-02 · Source page

Pages & changes

Tracked since 2026-03-27

Key pages

Weekly snapshots
artpiece.app/ Snapshot 2026-11-03

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Artpiece get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Artpiece and what platforms does it support?
Artpiece is catalogued under Casual & Puzzle: Puzzle. Color. Create Art.. Supported platforms: Mobile App.

Related products in this category

Games / Casual & Puzzle

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.